Dipòsit Digital de Documents de la UAB 2 registres trobats  La cerca s'ha fet en 0.02 segons. 
1.
9 p, 240.3 KB Review : Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19) / Pastick, Katelyn A. (Department of Medicine. University of Minnesota) ; Okafor, Elizabeth C. (Department of Medicine. University of Minnesota) ; Wang, Fan (Department of Experimental and Clinical Pharmacology. University of Minnesota) ; Lofgren, Sarah M. (Department of Medicine. University of Minnesota) ; Skipper, Caleb P. (Department of Medicine. University of Minnesota) ; Nicol, Melanie R. (Department of Experimental and Clinical Pharmacology. University of Minnesota) ; Pullen, Matthew F. (Department of Medicine. University of Minnesota) ; Rajasingham, Radha (Department of Medicine. University of Minnesota) ; McDonald, Emily G. (Clinical Practice Assessment Unit. Department of Medicine. McGill University Health Centre) ; Lee, Todd C. (Clinical Practice Assessment Unit. Department of Medicine. McGill University Health Centre) ; Schwartz, Ilan S. (Division of Infectious Diseases. Department of Medicine. Faculty of Medicine and Dentistry. University of Alberta) ; Kelly, Lauren E. (Department of Pediatrics and Child Health. Department of Pharmacology. University of Manitoba) ; Lother, Sylvain A. (Department of Medicine. Sections of Critical Care and Infectious Diseases. University of Manitoba) ; Mitjà, Oriol (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Letang, Emili (Barcelona Institute for Global Health (ISGlobal)) ; Abassi, Mahsa (Department of Medicine. University of Minnesota) ; Boulware, David R. (Department of Medicine. University of Minnesota)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. [...]
2020 - 10.1093/ofid/ofaa130
Open Forum Infectious Diseases, Vol. 7 Núm. 4 (16 2020) , p. ofaa130  
2.
6 p, 106.8 KB Antiretroviral Therapy (ART) Use, Human Immunodeficiency Virus (HIV)-1 RNA Suppression, and Medical Causes of Hospitalization Among HIV-Infected Intravenous Drug Users in the Late ART Era / Vallecillo Sánchez, Gabriel (Hospital del Mar) ; Mojal, Sergio (Departament d'Estadística i Investigació Operativa. Parc de Recerca Biomédica de Barcelona) ; Torrens, Marta (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ; Muga, Roberto (Hospital del Mar)
Background: Antiretroviral therapy (ART) has reduced the rates and changed the causes of hospital admission. However, human immunodeficiency virus-positive intravenous drug users (HIV-IDU) continue to have increased hospitalizations and discharge diagnosis are less defined in the late ART era. [...]
2014 - 10.1093/ofid/ofu010
Open Forum Infectious Diseases, Vol. 1 (june 2014)  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.